Akebia Therapeutics Inc. buy BTIG Research
Start price
29.11.23
/
50%
€0.92
Target price
29.11.24
€3.64
Performance (%)
10.52%
Price
24.05.24
€1.02
Summary
This prediction is currently active. The prediction currently has a performance of 10.52%. This prediction currently runs until 29.11.24. The prediction end date can be changed by BTIG_Research at any time. BTIG_Research has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Akebia Therapeutics Inc. | -4.049% | -4.049% |
iShares Core DAX® | -0.205% | 2.949% |
iShares Nasdaq 100 | 1.613% | 5.877% |
iShares Nikkei 225® | -0.740% | -1.256% |
iShares S&P 500 | 0.267% | 3.240% |
Comments by BTIG_Research for this prediction
In the thread Akebia Therapeutics Inc. diskutieren
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $4.00 price target on the stock.
Ratings data for AKBA provided by MarketBeat